The effects of as-needed nalmefene on patient-reported outcomes and quality of life in relation to a reduction in alcohol consumption in alcohol-dependent patients

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  François, Clément ^a   Rahhali, Nora ^a   Chalem, Ylana ^a   Sørensen, Per ^b   Luquiens, Amandine ^c   Aubin, Henri Jean ^c  

^a Lundbeck   (France)

^b H LUNDBECK A S   (Denmark)

^c HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NALMEFENE; PLACEBO; NALTREXONE;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; BEHAVIOR CHANGE; CAUCASIAN; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRINKER INVENTORY OF CONSEQUENCE; DRINKING BEHAVIOR; DRUG EFFECT; DRUG EFFICACY; EUROPEAN QUALITY OF LIFE 5 DIMENSION; FEMALE; HEALTH STATUS; HIGH RISK BEHAVIOR; HUMAN; INDIVIDUAL BEHAVIOR ASSESSMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ONSET AGE; POST HOC ANALYSIS; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF REPORT; SHORT FORM 36; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; DEMOGRAPHY; OUTCOME ASSESSMENT; QUESTIONNAIRE;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; DEMOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; PATIENT OUTCOME ASSESSMENT; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84936806629     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129289     Document Type: Article

References (42)

1. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, for the COMBINE Study Research Group. Combined pharmacotherapies and behavioural interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295: 2003-2017. PMID: 16670409
2. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011; 21: 655-679. doi: 10.1016/j.euroneuro.2011.07.018 PMID: 21896369
3. World Health Organisation. International Guide for Monitoring Alcohol Consumption and Related Harm. 2000: Available: www.who.int/substance-abuse/publications/alcohol/en/index.html. Accessed 9 March 2015.
4. Rehm J, Room R, Graham K, Monteiro M, Gmel G, Sempos C. The relationship of average volume of alcohol consumption and patterns of drinking to burden of disease: an overview. Addiction 2003; 98: 1209-1228. PMID: 12930209
5. Rehm J, Zatonksi W, Taylor B, Anderson P. Epidemiology and alcohol policy in Europe. Addiction 2011; 106 (Suppl 1): 11-19. doi: 10.1111/j.1360-0443.2010.03326.x PMID: 21324017
6. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009; 373: 2223-2233. doi: 10.1016/S0140-6736(09)60746-7 PMID: 19560604
7. Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull World Health Organ. 2004; 82: 858-866. PMID: 15640922
8. Adamson SJ, Heather N, Morton V, Raistrick D. Initial preference for drinking goal in the treatment of alcohol problems: II. Treatment outcomes. Alcohol Alcohol. 2010; 45: 136-142. doi: 10.1093/alcalc/agq005 PMID: 20130150
9. Substance Abuse and Mental Health Services Administration Office of Applied Studies. April 9, 2009. The NSDUH report: Alcohol Treatment: Need, utilization, and barriers. Rockville, MD.
10. European Medicines Agency-Guideline on the development of medicinal products for the treatment of alcohol dependence (2010). Available: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/03/WC500074898.pdf. Accessed January 2014.
11. Luquiens A, Reynaud M, Aubin HJ. Is controlled drinking an acceptable goal in the treatment of alcohol dependence? A survey of French alcohol specialists. Alcohol Alcohol. 2011; 46: 586-591. doi: 10.1093/alcalc/agr083 PMID: 21771742
12. NICE clinical guideline 115, Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence, Feb 2011. Available: http://www.nice.org.uk/nicemedia/live/13337/53191/53191.pdf. Accessed January 2014.
13. Donovan D, Mattson ME, Cisler RA, Longabaugh R, Zweben A. Quality of life as an outcome measure in alcoholism treatment research. J Stud Alcohol Suppl. 2005;(15:) : 119-139. PMID: 16223064
14. Dawson DA, Li TK, Chou SP, Grant BF. Transitions in and out of alcohol use disorders: their associations with conditional changes in quality of life over a 3-year follow-up interval. Alcohol Alcohol 2009; 44: 84-92. doi: 10.1093/alcalc/agn094 PMID: 19042925
15. Lahmek P, Berlin I, Michel L, Berghout C, Meunier N, Aubin HJ. Determinants of improvement in quality of life of alcohol-dependent patients during an inpatient withdrawal programme. Int J Med Sci. 2009; 6: 160-167. PMID: 19461935
16. Frischknecht U, Sabo T, Mann K. Improved drinking behaviour improves quality of life: a follow-up in alcohol-dependent subjects 7 years after treatment. Alcohol Alcohol. 2013; 48: 579-584. doi: 10.1093/alcalc/agt038 PMID: 23632806
17. Foster JH, Peters TJ, Kind P. Quality of life, sleep, mood and alcohol consumption: a complex interaction. Addict Biol. 2002; 7: 55-65. PMID: 11900623
18. Morgan MY, Landron F, Lehert P, for the New European Alcoholism Treatment Study Group. Improvement in quality of life after treatment for alcohol dependence with acamprosate and psychosocial support. Alcohol Clin Exp Res. 2004; 28: 64-77. PMID: 14745303
19. Günther O, Roick C, Angermeyer MC, König HH. The EQ-5D in alcohol dependent patients: relationships among health-related quality of life, psychopathology and social functioning. Drug Alcohol Depend. 2007; 86: 253-264. PMID: 16930855
20. Günther OH, Roick C, Angermeyer MC, König HH. Responsiveness of EQ-5D utility indices in alcohol-dependent patients. Drug Alcohol Depend. 2008; 92: 291-295. PMID: 17888587
21. Laaksonen E, Vuoristo-Myllys S, Koski-Jannes A, Alho H. Combining medical treatment and CBT in treating alcohol-dependent patients: effects on life quality and general well-being. Alcohol Alcohol. 2013; 48: 687-693. doi: 10.1093/alcalc/agt053 PMID: 23813295
22. Luquiens A, Reynaud M, Falissard B, Aubin HJ. Quality of life among alcohol-dependent patients: How satisfactory are the available instruments? A systematic review. Drug Alcohol Depend. 2012; 125: 192-202. doi: 10.1016/j.drugalcdep.2012.08.012 PMID: 22939877
23. Bart G, Schluger JH, Borg L, Ho A, Bidlack JM, Kreek MJ. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacol. 2005; 30: 2254-2262.
24. Mann K, Bladström A, Torup L, Gual A, van den Brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry 2013; 73: 706-713. doi: 10.1016/j.biopsych.2012.10.020 PMID: 23237314
25. Gual A, He Y, Torup L, van den Brink W, Mann K; for the ESENSE 2 Study Group. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. 2013; 23: 1432-1442. doi: 10.1016/j.euroneuro.2013.02.006 PMID: 23562264
26. van den Brink W, Aubin HJ, Bladström A, Torup L, Gual A, Mann K. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol. 2013; 48: 570-578. doi: 10.1093/alcalc/agt061 PMID: 23873853
27. European Medicines Agency-Find medicine- Selincro. 2013. Available: http://www.ema.europa.eu/ema/index.jsp?Curl=pages/medicines/human/medicines/002583/human-med-001620.jsp&mid=WC0b01ac058001d124. Accessed January 2014.
28. Starosta AN, Leeman RF, Volpicelli JR. The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders. J Psychiatr Pract. 2006; 12: 80-89. PMID: 16728904
29. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders 4th ed. Text Revision (DSM-IV-TR). 2000; Washington, DC: American Psychiatric Association.
30. Lecrubier Y, Sheehan DV, Weiller E, Amorim P, Bonora I, Sheehan KH, et al. The MINI International Neuropsychiatric Interview (M.I.N.I.). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 1997; 12: 224-231.
31. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. 1994; Boston, MA: The Health Institute. doi: 10.1007/s11136-010-9658-9 PMID: 20440565
32. Maruish ME. User's manual for the SF-36v2 Health Survey (3rd ed.). 2011; Lincoln, RI: QualityMetric Inc.
33. Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000; 17: 13-35.
34. EuroQoL Group. EuroQoL - a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208. PMID: 10109801
35. Dolan P. Modeling valuations for Euroqol health states. Med Care 1997; 35: 1095-1108. PMID: 9366889
36. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK general population survey. 1995; The University of York. Available: http://www.york.ac.uk/media/che/documents/papers/discussionpapers/CHE%20Discussion%20Paper%20138.pdf. Accessed 9 March 2015.
37. Miller WR, Tonigan JS, Longabaugh R. In: Mattson M.E. (Ed.) The Drinker Inventory of Consequences (DrInC): An Instrument for Assessing Adverse Consequences of Alcohol Abuse. Project MATCH Monograph Series, 1995; Vol. 4. Rockville, Maryland: National Institute on Alcohol Abuse and Alcoholism.
38. Daeppen JB, Krieg MA, Burnand B, Yersin B. MOS-SF-36 in evaluating health-related quality of life in alcohol-dependent patients. Am J Drug Alcohol Abuse 1998; 24: 685-694. PMID: 9849778
39. Pettinati HM, Gastfriend DR, Dong Q, Kranzler HR, O'Malley SS. Effect of extended-release Naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. Alcohol Clin Exp Res. 2009; 33: 350-356. doi: 10.1111/j.1530-0277.2008.00843.x PMID: 19053979
40. Rehm J, Roerecke M. Reduction of drinking in problem drinkers and all-cause mortality. Alcohol Alcohol. 2013; 48: 509-513. doi: 10.1093/alcalc/agt021 PMID: 23531718
41. Cuijpers P, Riper H, Lemmers L. The effects on mortality of brief interventions for problem drinking: a meta-analysis. Addiction 2004; 99: 839-845. PMID: 15200579
42. Stein MD, Mulvey KP, Plough A, Samet JH. The functioning and well being of persons who seek treatment for drug and alcohol use. J Subst Abuse 1998; 10: 75-84. PMID: 9720008